Key facts
- Izalontamab Brengitecan showed significant improvements in overall survival and progression-free survival.
- The drug is being developed by Bristol-Myers Squibb Co.
- Positive results were observed in patients with triple-negative breast cancer (TNBC).
- Positive results were observed in patients with esophageal squamous cell carcinoma (ESCC).
Bristol-Myers Squibb Co announced that its drug, Izalontamab Brengitecan, has shown significant improvements in both overall survival (OS) and progression-free survival (PFS). These positive clinical trial results were specifically noted in patient groups suffering from triple-negative breast cancer (TNBC) and esophageal squamous cell carcinoma (ESCC). The drug's development by Bristol-Myers Squibb positions it as a potential new therapeutic option for these challenging cancer types.
